Uber Q2 2026 Results Signal Delivery Growth

Uber Q2 2026 results show delivery-led revenue growth and record engagement, while Q3 bookings of $59.25 billion and FX headwinds temper near-term flows.

August 05, 2026·2 min read
View all news articles
Flat vector delivery scooter with dimming backdrop to reflect Uber Q2 2026 results and $58 billion gross bookings.

KEY TAKEAWAYS

  • Gross bookings rose 22% to $58.0 billion, led by delivery engagement.
  • Revenue rose 11% to $14.2 billion; adjusted EBITDA was $2.8 billion.
  • Management set Q3 bookings midpoint at $59.25 billion, slightly below FactSet, and warned FX would trim bookings growth.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Uber Technologies Inc. (UBER) reported second-quarter 2026 results on Aug. 5, showing revenue growth driven by delivery and record consumer engagement. Management set third-quarter bookings guidance slightly below estimates and warned that foreign-exchange headwinds could reduce bookings growth.

Quarter Results and Metrics

Uber filed a Form 8-K with the SEC on Aug. 3, including Exhibit 99.1 with the earnings release, and a Form 10-Q for the quarter ended June 30, 2026. The results release, distributed via Business Wire at 6:55 a.m. ET on Aug. 5, said the platform reached record consumers and engagement. The company added more first-time users over the past twelve months than in any period in the last five years.

Gross bookings for Q2 2026 rose 22% year over year on a constant-currency basis to $58.0 billion. Revenue increased 11% to $14.2 billion. On a GAAP basis, income from operations was $1.9 billion, net income was $2.4 billion, and diluted earnings per share (EPS) was $1.17. Adjusted EBITDA, a proxy for operating profit, was $2.8 billion, non-GAAP EPS was $0.81, and free cash flow totaled $2.8 billion. These figures highlight strong near-term cash generation as Uber expands its consumer base and engagement across delivery and mobility.

Guidance and Investment Plans

Uber set third-quarter bookings guidance at a midpoint of $59.25 billion, slightly below the FactSet average estimate of $59.33 billion. Management also forecast adjusted earnings below Wall Street estimates and said foreign-exchange effects would weigh on bookings growth.

The company reaffirmed plans to invest heavily in robotaxis and acquisitions, signaling continued capital intensity rather than an immediate focus on margin improvement. This combination of strong cash flow and ongoing strategic spending frames investor attention on balancing growth and currency pressures with long-term investments.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

AppLovin Stock Downgrade Tests Growth Thesis

AppLovin Stock Downgrade Tests Growth Thesis

AppLovin stock downgrade by Bank of America on Aug. 11 followed the Aug. 5 8-K and Q3 guidance and pressured shares while raising debate over growth.

Joby Aviation Acquisition Tests Financing Plans

Joby Aviation Acquisition Tests Financing Plans

Joby Aviation acquisition expands the defense footprint and files an at-the-market offering, creating a funding path while raising dilution concerns.

Lumentum Earnings Rise on AI Optical Demand

Lumentum Earnings Rise on AI Optical Demand

Lumentum earnings showed stronger Q4 results and above-range Q1 FY2027 guidance citing AI data-center optical demand, supporting bullish trader interest.

Micron Price Targets Show Wide Upside Range

Micron Price Targets Show Wide Upside Range

Micron price targets rose as AI memory demand tightened HBM supply; aggregator averages imply sizable upside while traders weigh the DRAM pricing outlook.

Spotify AI Persona Labels Limit Recommendations

Spotify AI Persona Labels Limit Recommendations

Spotify AI Persona labels will flag suspected AI artists and exclude them from recommendations by default, a product change that could shift discovery.

Capricor Therapeutics Class Action After FDA Data Concerns

Capricor Therapeutics Class Action After FDA Data Concerns

Capricor Therapeutics class action alleges misleading Deramiocel claims after FDA briefing concerns over HOPE-3, creating near-term legal and trading risk.